A novel multidisciplinary intervention for long-term weight loss and glycaemic control in obese patients with diabetes by Lih, A. et al.
PUBLISHED VERSION  
http://hdl.handle.net/2440/94149  
 
Anna Lih, Lorraine Pereira, Ramy H. Bishay, Johnson Zang, Abdullah Omari, Evan Atlantis, and Nic 
Kormas 
A novel multidisciplinary intervention for long-term weight loss and glycaemic control in obese 
patients with diabetes 
Journal of Diabetes Research, 2015; 2015:729567-1-729567-7 
© 2015 Anna Lih et al. This is an open access article distributed under the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 





























A Novel Multidisciplinary Intervention for Long-Term Weight
Loss and Glycaemic Control in Obese Patients with Diabetes
Anna Lih,1,2 Lorraine Pereira,1,2 Ramy H. Bishay,1,2 Johnson Zang,1,2 Abdullah Omari,3,4
Evan Atlantis,5,6 and Nic Kormas1,2
1Department of Endocrinology & Metabolism, Concord Repatriation General Hospital, Rhodes, NSW 2139, Australia
2Sydney Medical School, University of Sydney, Sydney, NSW 2006, Australia
3University of New South Wales Medical Program, University of New South Wales, Sydney, NSW 2052, Australia
4Department of Vascular Medicine, St. Vincent’s Hospital, Darlinghurst, Sydney, NSW 2010, Australia
5School of Nursing and Midwifery, University of Western Sydney, Campbelltown, NSW 2560, Australia
6School of Medicine, University of Adelaide, Adelaide, SA 5005, Australia
Correspondence should be addressed to Ramy H. Bishay; ramy.bishay@sswahs.nsw.gov.au
Received 9 February 2015; Accepted 25 March 2015
Academic Editor: Francis M. Finucane
Copyright © 2015 Anna Lih et al.This is an open access article distributed under the Creative CommonsAttribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction. Obesity and diabetes are difficult to treat in public clinics. We sought to determine the effectiveness of the Metabolic
Rehabilitation Program (MRP) in achieving long-term weight loss and improving glycaemic control versus “best practice” diabetes
clinic (DC) in obese patients using a retrospective cohort study.Methods. Patients with diabetes and BMI > 30 kg/m2 who attended
the MRP, which consisted of supervised exercise and intense allied health integration, or the DC were selected. Primary outcomes
were improvements in weight and glycaemia with secondary outcomes of improvements in blood pressure and lipid profile at 12 and
30 months. Results. Baseline characteristics of both cohorts (40 MRP and 40 DC patients) were similar at baseline other than age
(63 in MRP versus 68 years in DC, 𝑃 = 0.002). At 12 months, MRP patients lost 7.65 ± 1.74 kg versus 1.76 ± 2.60 kg in the DC group
(𝑃 < 0.0001) and 9.70 ± 2.13 kg versus 0.98 ± 2.65 kg at 30 months (𝑃 < 0.0001). Similarly, MRP patients had significant absolute
reductions in %HbA1c at 30 months versus the DC group (−0.86 ± 0.31% versus 0.12% ± 0.33%, 𝑃 < 0.038), with nonsignificant
improvements in lipids and blood pressure in MRP patients. Conclusion. Further research is needed to establish the MRP as an
effective strategy for achieving sustained weight loss and improving glycaemic control in obese patients with type 2 diabetes.
1. Introduction
Obesity is a serious condition strongly associated with excess
dietary intake and physical inactivity. It is estimated that 205
million men and 297 million women older than 20 years
worldwide were obese in 2008 [1]. The prevalence of obesity
in Australia almost tripled since 1980 [1] and results from
the Australian Health Survey estimate that 28.3% of adults
were obese in 2011 [2]. One of the consequences of rising
prevalence of obesity globally has been the concomitant
increase in type 2 diabetes mellitus (T2DM) [3]. Indeed, the
International Diabetes Federation (IDF) estimated that 366
million people worldwide, or 8% of adults, now have diabetes
[4].
Once comorbid, diabetes significantly increases the
health and economic burden of obesity, being the most
common reason for renal dialysis, blindness in people less
than 60 years of age, nontraumatic lower-limb amputation,
and cardiovascular disease [4]. The rising health burden of
T2DM disproportionately affects older, obese, and physically
inactive people [5]. Conversely, weight loss has been demon-
strated to significantly improve glycaemic control in obese
patients with diabetes, and this relationship ismost evident in
bariatric studieswith remission of diabetes achieved in 73%of
surgical patients versus 13% in a conventional therapy group
[6]; this outcome was likely due to a number of factors in
addition to weight loss such as altered delivery of nutrients,
gut hormone changes, and alterations to bile acid and amino
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315 patients identified
250 diabetes clinic 62 MRP
50 failed to follow up
12 did not fulfill BMI criteria
144 declined consent or 
not reachable 
4 not matched with MRP
40 DC patients 40 MRP patients
5 did not continue review 
at the clinic
4 not matched with DC
13 <12 months of review
in the period 2004–2007
Figure 1: Study participants selection and case-matching.
acid metabolism [7]. Nonetheless, lifestyle changes aimed
at achieving a healthy body weight and moderate physical
activity should be the initial intervention for all obese patients
with pre- and established diabetes [8–10].
Weight loss is complex in obese patients with diabetes
where many antidiabetic medications can increase weight,
especially insulin [11]. Additionally, sustained weight loss is
difficult to achieve as most obese patients regain the majority
of the weight initially lost within 2–5 years [12, 13]. The
problem of clinically meaningful and sustainable outcomes
was also gleaned from the recent cessation of the Look
AHEAD trial [14], which, despite achieving good 1-year
weight losses of 8.6%of initial bodyweight in the intervention
group, only verymodest losses were achieved at 10 years (6%).
Current “best practice” diabetes clinics (DC) utilizing
medical, nursing, and limited allied health support are the
current standard of care for managing patients with T2DM.
However, it is questionable whether the DC offers the best
care long-term in obese patients, especially since obesity
is associated with reduced responsiveness to blood glucose
lowering medications over time, and in turn increased med-
ication and insulin dosages may induce further weight gain,
perpetuating the problem [16, 17].
With some exceptions [18–20] there is paucity of data
evaluating long-term outcomes in obese patients in diabetes
clinics. We have recently reported that weight loss and
improved glycaemic control can be achieved and maintained
over a 3-year period in a small population of patients enrolled
in an intensive, multidisciplinary lifestyle intervention called
the Metabolic Rehabilitation Program (MRP), the first of its
kind in Australia [21]. However, the long-term benefits of
the MRP compared with “best practice” DC are unknown.
We hypothesized that obese patients with T2DM enrolled in
the MRP would achieve significant weight loss and improved
glycaemic control when compared with DC patients and that
these results would be durable long-term using a retrospec-
tive cohort study design.
2. Materials and Methods
2.1. Study Design. This was a retrospective cohort study
conducted at Concord Repatriation General Hospital, a
major teaching hospital and tertiary referral center in Sydney,
Australia. In all, 40 MRP patients met inclusion criteria
and were case-matched with 40 DC patients with respect
to BMI, age, gender, glycaemic control, and duration of
diabetes (Figure 1). Exclusion of participants included those
who could not be contacted to obtain consent, BMI less
than 30 kg/m2, and/or inability to verify anthropometric
and medical history. Diagnosis of T2DM was established if
patients had fasting plasma glucose equal to or greater than
126mg/dL (7.0mmol/L) or a 75 g OGTT consistent with a
diagnosis of diabetes. Participants were enrolled in either the
MRP or the DC for a minimum of 12 months between the
periods from 2004 to 2007 and had follow-up clinical data for
30months.The studywas approved by the Sydney SouthWest
Area Health Service Human Research Ethics Committee; all
patients were contacted to obtain informed consent for study
inclusion.
2.2. Metabolic Rehabilitation Program (MRP). TheMRP was
established in 2003 and designed specifically as a compre-
hensive lifestyle program or “one-stop shop” for managing
complex obese patients with T2DM. All patients in the MRP
had a diagnosis of T2DM and BMI greater than 30 kg/m2
and were at least 18 years of age. Exclusions included type
1 diabetes mellitus, pregnancy, previous bariatric surgery
during the study period, eating disorders, major comorbidity
limiting physical exercise, or conditions associated with
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unintentional weight loss such as malignancy, HIV, dialysis,
or home oxygen.
The primary intervention of the MRP was twofold: to
achieve significant and sustainable weight loss and improved
glycaemic control. This program, outlined previously [21],
which included a collaborative multidisciplinary team super-
vised by an endocrinologist (NK) specializing in obesity
and diabetes was conducted monthly for 6 months and
then every 2-3 months thereafter. Allied health integration
consisted of review by a dietician upon enrolment into the
MRP, with follow-up consultations on a 6-weekly basis and
an annual review. Concurrently, there were also eight group
sessions conducted to assist patients with implementing
individualized diet programs and meal replacements (e.g.,
Optifast). In addition, there was a clinical review by a diabetes
educator upon enrolment and subsequently twice a year. An
on-site psychologist was available for an initial consultation
and four group sessions conducted throughout the program.
The exercise program was supervised by physiotherapists
and exercise physiologists for 6 days a week to prescribe
and supervise exercise. Weight losing medications were not
used. Oral hypoglycaemic pharmacotherapies were titrated
at the discretion of the treating endocrinologist based on
national guidelines current at the time of the study [22].
The educational component of the MRP was adopted from
the Bodylines program, a validated educational weight loss
program used successfully in previous studies [23].
The intensive exercise program consisted of 330 minutes
ofmoderate intensity physical activity aweek.This comprised
a compulsory 180 minutes of supervised exercise classes at
an on-site gymnasium in the hospital and a further 150
minutes on off-clinic days. Exercise intensity was based on
achievement of a heart rate (HR) response of 60–80% of pre-
dictedmaximalHR (average range 110–140 beats perminute),
taking into consideration age, fitness level, risk of injury,
and cardiorespiratory risk factors. The prescribed exercises
included 20–30minutes each of aerobic exercises (treadmills,
biking, step-up boxes, and walking) and resistance training
(pin-loaded machines and free weights). Whenever possi-
ble, the supervising endocrinologist would reduce weight-
promoting antiglycaemic medications and substitute them
with weight neutral medications as clinically indicated or
cease medications altogether.
2.3. Diabetes Clinic (DC). Diabetes clinic patients were seen
at the outpatient hospital clinic and managed by opti-
mizing glycaemic control and risk factor modification of
hypertension and dyslipidaemia and mitigating long-term
micro- and macrovascular complications of diabetes using
pharmacological and nonpharmacological methods based on
“best practice” guidelines at the time of the study [22]. The
DC consisted of consultations with endocrinologists (AL)
specializing in diabetes and obesity medicine at 3–6 monthly
intervals and regular but less frequent appointments with the
same diabetes nurse educators and dietitians as in the MRP.
Referrals to other outpatient services and specialists such as
psychologists, podiatrists, ophthalmologists, nephrologists,
and cardiologists were carried out as required based on
clinical guidelines at the time of study.
2.4. Patient and Laboratory Assessment. The interval of med-
ical reviews was consistent between the two groups, with
patients being reviewed at the start of clinical encounter
and then at 3–6 monthly intervals. The collection of data
for all primary and secondary outcomes was obtained at
baseline, 12 months, and 30 months. Our primary outcome
data included weight (kg), BMI, and %HbA1c whilst our
secondary aims included total, high-density (HDL) and low-
density (LDL) lipoprotein cholesterol, total triglycerides, and
blood pressure. The calculation of BMI was determined
by the standard formula weight (kg) divided by height
(meters) squared. Improvement in glycaemic control was
defined as greater than 1% reduction. The commercial assay
used was the HPLC assay (BIORAD Variant II TURBO).
An improvement in weight was defined as a significant
decrease whereas successful weight loss was defined as 5%
or more of baseline weight lost, both at either 12 or 30
months [24]. Percentage change in all anthropometric and
laboratory data was calculated as the measured value minus
baseline value divided by baseline value and multiplied by
100%.
2.5. Statistical Methods. This study was retrospective and
sought to recruit 90 participants in total. It was determined
that this number of participants would provide the study with
a power of 80% to detect a clinically important reduction
of ≥5% in weight, with a two-sided type 1 error of 5% and
a potential withdrawal rate of 10%. Descriptive analysis was
performed on the baseline demographic and anthropometric
characteristics between the selected patient groups. To deter-
mine differences between the MRP and DC groups, 𝜒2 test
was used for categorical variables and the Student’s 𝑡-test and
Mann-Whitney 𝑈 test were used for continuous variables.
Analysis of covariance (ANCOVA) was used to determine
group differences adjusting for covariates of age, gender, and
BMI. A 𝑃 value < 0.05 was considered statistically significant.
All statistical analyses were performed using SPSS Statistics
Version 19 (IBM Corporation, Armonk, NY, USA).
3. Results
Between 2004 and 2007, 80 participants were included in the
analysis (Figure 1). The baseline characteristics of the partic-
ipants are described in Table 1. The mean age of participants
in the DC group was 5 years more than those enrolled in the
MRP (68.3 ± 9.2 versus 63.3 ± 8.5 years), 𝑃 = 0.002. However,
the majority of patients were between the ages of 51 and 80
years (45% in both groups). The BMI, gender distribution,
and duration of diabetes were not significantly different
between the groups. Initial glycaemic control was poorer in
the MRP group than the DC group (%HbA1c of 8.2 ± 1.6
versus 7.9 ± 1.9 or 66.3 ± 17.5 versus 63.2 ± 20.8mmol/mol,
resp.) though this difference was nonsignificant.
At 12 months, the MRP group lost significantly more
weight compared to theDCcohort (7.65± 1.74 kg versus 1.76±
2.60 kg, Table 2). At 30 months, MRP patients achieved a
mean weight loss of 9.70 ± 2.13 kg versus lesser gains in the
DC patients of 0.98 ± 2.65 kg (𝑃 < 0.0001). In the DC group,
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Gender Female 55% Female 51% 0.85
Male 45% Male 49%
Mean age (years) 63.3 ± 8.5 68.3 ± 9.2 0.002∗∗
Weight (kg) 106.2 ± 18.2 100.8 ± 17.9 0.78
BMI (kg/m2) 20–25 37.5 ± 5.3 37.7 ± 6.3 0.59
HbA1c
(%) ≤7%(range 6.5–7.5) 8.2 ± 1.6 7.9 ± 1.9 0.56
(mmol/mol) ≤53(range 48–58) 66.3 ± 17.5 63.2 ± 20.8
Duration of diabetes ≤10 years 21 (27.3%) 21 (27.3%) 0.74
10 years 19 (24.7%) 19 (24.7%)
SBP (mmHg) <130 136 ± 18.6 141 ± 16.1 0.12
DBP (mmHg) <80 79 ± 9.2 77 ± 11.1 0.51
HDL (mM) ≥1 1.3 ± 0.8 1.2 ± 0.3 0.29
LDL (mM) <2.5 2.6 ± 0.9 2.6 ± 0.7 0.90
Triglycerides (mM) <2 2.1 ± 1.0 2.2 ± 1.0 0.66
∗National guidelines are based on [15]. Values are shown as means (±SD). Significance is set at 𝑃 < 0.05 and highlighted by asterisk (∗∗).
HbA1c, serum glycosylated haemoglobin expressed as % and mmol/mol; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, serum high-density
lipoprotein cholesterol; LDL, serum low-density lipoprotein cholesterol.
13% of participants regained weight versus 8% in the MRP
group.
Glycaemic control was markedly improved in the inter-
vention group versus the DC group at 12 months, with
absolute percentage-point reduction in %HbA1c of 0.95 ±
0.28 versus 0.35 ± 0.34, respectively (𝑃 = 0.08). The
improvement in glycaemic control continued at 30 months,
with a significant reduction in %HbA1c of 0.86 ± 0.31 whilst
the DC group had a reduction of 0.12% ± 0.33 (𝑃 < 0.038).
Participants that lost weight had improved glycaemic
control; 60% of participants that lost weight demonstrated
improved %HbA1c at 12 months. Those patients that reached
successful weight loss (≥5%) at 12 months were greater in the
MRP versus the DC cohort (35% versus 10%,𝑃 < 0.001).This
improvement was also more likely to be maintained long-
term at 30 months in the MRP versus the DC group (36%
versus 12%, 𝑃 < 0.001).
At 30 months, participants who achieved a %HbA1c less
than 5.7 were found exclusively in the MRP (representing
3.9% of all patients) and achieved >5% weight loss. For
%HbA1c within a range of 5.7–6.5, 7.8% of participants
achieved this target range in both theDC andMRP treatment
arm and all had documented weight loss, albeit some fell
short of 5% weight loss at 30 months.
There was also a reduction in systolic blood pressure
(SBP) of 9.50 ± 3.28mmHg in the MRP group versus 0.77 ±
3.91mmHg in the DC cohort at 12 months, though this was
not statistically significant in this small study. There was
also a statistically significant improvement in HDL levels at
30 months as well as nonsignificant improvements in LDL,
triglycerides, and diastolic blood pressure.
4. Discussion
This study demonstrated that an intensive multifaceted
lifestyle intervention was superior for achieving long-term
weight loss and improvements in glycaemic control in obese
adults with type 2 diabetes compared with traditional “best
practice” in a diabetes clinic, in the Australian public health
system.Our findings should informboth diabetes and obesity
practitioners and health policy decision-makers in Australia.
Remission of diabetes in obese patients is now thought
to be possible and has been achieved in those who have
achieved long-termweight loss following bariatric surgery, as
demonstrated by the randomized control study by Dixon et
al. and the more recent STAMPEDE study [6, 25, 26]. Simi-
larly, using nonsurgical approaches, severe caloric restriction
(600 kcal/day) in 11 obese patients with diabetes demon-
strated reversal of beta cell dysfunction and remission of
diabetes with a reduction of%HbA1c from 7.4 to 6 [27]. In our
study employing nonsurgical, intensive integration of allied
health, 60% of participants that lost weight demonstrated
improved %HbA1c at 12 months, with MRP participants
achieving more successful weight loss (≥5%) at 1 year versus
the DC cohort, and were nearly three times more likely to be
maintained long-term. Although notmeasured specifically in
this study, our small study raises the possibility of diabetes
remission in a population of obese patients using a nonsurgi-
cal approach.
Traditional diabetes clinics often lack a structured weight
management program and there is little data evaluating the
efficacy of traditional diabetes clinics for obese people with
diabetes. One study [28] evaluated a diabetes clinic with
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Table 2: Percent changes in weight, BMI, %HbA1c, and other clin-
ical outcomes of patients enrolled in the Metabolic Rehabilitation







Baseline (kg) 106.2 ± 18.2 100.8 ± 17.9 0.78
Δ12 months −7.65 ± 1.74 −1.76 ± 2.60 <0.0001∗∗
Δ30 months −9.70 ± 2.13 −0.98 ± 2.65 <0.0001∗∗
BMI
Baseline (kg/m2) 37.5 ± 5.3 37.7 ± 6.3 0.59
Δ12 months −7.73 ± 1.83 −2.23 ± 1.74 <0.0001∗∗





(66.3 ± 17.5) 7.9 ± 1.9 0.56
Δ12 months −0.95 ± 0.28 −0.35 ± 0.34 0.08
Δ30 months −0.86 ± 0.31 −0.12 ± 0.33 0.04∗∗
ΔSBP
Baseline (mmHg) 136 ± 18.6 141 ± 16.1 0.12
Δ12 months −9.50 ± 3.28 −0.77 ± 3.91 0.15
Δ30 months −7.51 ± 3.47 −3.37 ± 4.23 0.21
ΔDBP
Baseline (mmHg) 79 ± 9.2 77 ± 11.1 0.51
Δ12 months −5.20 ± 1.72 −3.49 ± 2.29 0.39
Δ30 months −4.39 ± 1.93 −4.76 ± 2.22 0.82
ΔHDL
Baseline (mM) 1.3 ± 0.8 1.2 ± 0.3 0.29
Δ12 months −0.03 ± 0.16 −0.09 ± 0.06 0.14
Δ30 months −0.049 ± 0.15 −0.07 ± 0.07 0.04∗∗
ΔLDL
Baseline (mM) 2.6 ± 0.9 2.6 ± 0.7 0.90
Δ12 months 0.12 ± 0.19 −0.23 ± 0.18 0.35
Δ30 months −0.37 ± 0.18 −0.35 ± 0.16 0.62
ΔTriglycerides
Baseline (mM) 2.1 ± 1.0 2.2 ± 1.0 0.66
Δ12 months −0.26 ± 0.23 −0.29 ± 0.21 0.98
Δ30 months −0.53 ± 0.22 −0.11 ± 0.23 0.13
Values are shown as net change from baseline ± standard deviation (SD).
Significance is set at𝑃 < 0.05 and highlighted by asterisk (∗∗). Abbreviations
are as described in Table 1.The covariates of age, gender, and BMIwere taken
into account in the analysis.
a structured weight management program in a community
hospital and achieved a %HbA1c of less than 7% in 42%
of patients, while other studies emphasizing optimal blood
pressure and lipid profile targets achieved a %HbA1c less
than 7% in 20% of patients at 30 months [29, 30]. This
highlights the importance of weight management in diabetes
clinics. Our small study revealed that even obese patients
with diabetes for an appreciable duration and mostly in
their 6th decade of life can achieve an absolute reduction of
nearly 1 point in %HbA1c at 1 year and 0.86 after 30 months
or %HbA1c of 7.25 and 7.34, respectively, with structured
exercise and integration of dietetics and physiotherapy.
Weight loss, in particular long-term losses, is difficult to
achieve in obese patients with diabetes due to many factors.
However,modest weight loss in diabetic patients at 12months
has been previously demonstrated [31, 32]whilst other studies
have shown rebound weight gain of up to 50–66% within
two years [11], while only few studies have shown sustained
long-term weight loss. The Finnish study [18], a three-year
trial which randomized obese patients (BMI 31.4 kg/m2) with
impaired glucose tolerance to either conventional therapy
or intensified lifestyle modification program, showed only
modest weight loss of 3.5 kg (versus 9.7 kg in our study). A
study by Brown et al. compared weight loss achieved with
either dietary versus behavioural interventions in a 2-year
trial and demonstrated that dietary interventions achieved
significantly more weight loss (9 kg versus 3 kg, resp.) [33]
than behavioural interventions, emphasizing the importance
of a structured eating plan and the synergistic effect of
combined behavioral and dietetic interventions as employed
by our study. Our study achieved superior weight loss, with
MRP patients losing on average 7.65 ± 1.74 kg at 12 months
compared with 1.76 kg in the DC group. Furthermore, in
comparison with previous trials, our patient cohort were able
tomaintain significant weight loss up to 30months with 9.7 ±
2.13 kg in the MRP compared with only 0.98 ± 2.65 kg in the
DC.This not only demonstrates the long-termeffectiveness of
theMRPbut also suggests the need for successful programs to
be continued beyond 2 years as rebound weight gain is often
seen in this time period.
The LookAHEAD study [34, 35] is one of the largest trials
evaluating intensified lifestyle programs directed at obese
diabetes patients. The group aimed for a reduction in weight
of ≥10% at 12 months in enrolled participants. The profile
of patients enrolled in this intensified program had a mean
BMI of 36 kg/m2 and HbA1c of 7.2%. The participants in our
study in both groups had a mean BMI of 37 kg/m2 and mean
HbA1c of 8%, reflecting the higher metabolic burden in our
patients. The achieved weight loss at 3 years was 5.5% in
the intensified treatment arm, in contrast to the MRP group,
which achieved weight loss of 9.8% at 30 months. We have
previously commented that this apparent discrepancy may
be due to the greater amount of prescribed and supervised
exercise sessions of participants in the MRP group [21] and
is substantiated by the work of prior studies [36–38] which
have advocated for the importance of exercise in maintaining
glycaemic control in patients with diabetes.
Many studies have failed to show long-term amelioration
of cardiometabolic risk factors to 30 months [12, 39]. Our
study demonstrated reductions in systolic blood pressure,
LDL cholesterol, and triglycerides as well as an increase in
HDL cholesterol, although, with the exception of HDL, these
did not reach statistical significance between groups. This
was most likely due to multiple factors including pharma-
cological unloading, anticipated increase in blood pressure
following initial weight loss [40], and the small study sample.
Furthermore, our study did not evaluate adherence to lipid
lowering and antihypertensive pharmacological agents and
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represents a reasonable avenue for a larger, more rigorous
study.
Several limitations of our study warrant further consid-
eration. The results of this retrospective study were based
on two small cohorts reviewed over 30 months in routine
clinical practice. However, this study was adequately powered
to detect clinically meaningful weight loss and is the first
to have assessed the success of weight loss and glycaemic
control long-term in specialist clinics in Australia. Other
study limitations and potential sources of bias include the
self-selection of patients into each intervention (nonrandom
treatment allocation) and the fact that MRP patients were
younger and perhaps more motivated. Socioeconomic status
was also not directly studied and selected patients who were
mostly limited resided within a 10 km radius of the study site.
There are many logistical and financial challenges in
developing multifaceted programs with the goal of achieving
long-term weight loss as well as limitations to the availability
of human resources with expertise in weight management.
Future implementation research should focus on facilitating
the feasibility and applicability of intensive lifestyle inter-
vention for diabetes and obesity management in the public
health system, with increasingly diminishing resources. It
is plausible that the cost of such programs may be offset
by reduction in the burden of disease, the cost of treating
complications of diabetes and obesity, and pharmacological
unloading.Therefore, future studies employing a randomised
controlled trial comparing the efficacy and cost-effectiveness
of patients enrolled in theMRPwith standard care or surgery,
with a larger population size, longer follow-up, and data on
pharmacological agents, especially given the era of newer oral
hypoglycaemic agents (e.g., DPP-4 inhibitors, GLP-1 agonists,
and SGLT2 inhibitors) would be invaluable. These studies
may potentially change current guideline-driven models of
care.
5. Conclusions
The findings of this study show that intensive multidisci-
plinary specialist care was more effective in achieving long-
term weight loss and improving glycaemic control in obese
patients with type 2 diabetes compared with “best-practice”
diabetes clinic care. Further research on the feasibility and
applicability of this model of care in other settings and
countries is required to inform health policy-makers and
specialist practitioners of the best “obesity and diabetes care”
long-term.
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